User profiles for Geoffrey R. Oxnard
 | Geoffrey R. Oxnard, MDLoxo Oncology @ Lilly Verified email at loxooncology.com Cited by 25468 |
Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review
Purpose.— Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
[HTML][HTML] New targetable oncogenes in non–small-cell lung cancer
The identification of oncogenic driver mutations underlying sensitivity to epidermal growth
factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge …
factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge …
[HTML][HTML] Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
MC Liu, GR Oxnard, EA Klein, C Swanton, MV Seiden… - Annals of …, 2020 - Elsevier
Background Early cancer detection could identify tumors at a time when outcomes are
superior and treatment is less morbid. This prospective case-control sub-study (from …
superior and treatment is less morbid. This prospective case-control sub-study (from …
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung
cancer whose tumors had developed resistance to the epidermal growth factor receptor (…
cancer whose tumors had developed resistance to the epidermal growth factor receptor (…
[HTML][HTML] Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer
Purpose Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR T790M. …
(TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR T790M. …
[HTML][HTML] Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
…, GR Oxnard, R Dziadziuszko… - … England Journal of …, 2015 - Mass Medical Soc
Background Non–small-cell lung cancer (NSCLC) with a mutation in the gene encoding
epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but …
epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but …
Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
GR Oxnard, CP Paweletz, Y Kuang, SL Mach… - Clinical cancer …, 2014 - AACR
Purpose: Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow
noninvasive assessment of tumor biology, yet many existing assays are cumbersome and …
noninvasive assessment of tumor biology, yet many existing assays are cumbersome and …
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
Purpose: Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after a median of 10 …
develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after a median of 10 …
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
Background: The epidermal growth factor receptor (EGFR) mutation T790M is reported in
approximately 50% of lung cancers with acquired resistance to EGFR inhibitors and is a …
approximately 50% of lung cancers with acquired resistance to EGFR inhibitors and is a …